Unraveling the active conformation of urotensin II.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2004-02-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM0309912PMID 15027856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor.

  2004cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

  2002cited by this paper
• Is urotensin‐II the new endothelin?

  2002cited by this paper
• A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

  2002cited by this paper
• Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues.

  2002cited by this paper
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002cited by this paper
• Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

  2002cited by this paper
• Cardiostimulant effects of urotensin‐II in human heart in vitro

  2001cited by this paper
• Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

  2000cited by this paper
• Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat

  2000cited by this paper
• Urotensin II: fish neuropeptide catches orphan receptor.

  2000cited by this paper
• Human urotensin‐II is a potent spasmogen of primate airway smooth muscle

  2000cited by this paper
• Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1

  2000cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Mimicry of beta II'-turns of proteins in cyclic pentapeptides with one and without D-amino acids.

  1999cited by this paper
• Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

  1999cited by this paper
• Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction

  1999cited by this paper
• Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

  1998cited by this paper
• Torsion angle dynamics for NMR structure calculation with the new program DYANA.

  1997cited by this paper
• Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures.

  1997cited by this paper
• "Teflon-coated peptides": hexafluoroacetone trihydrate as a structure stabilizer for peptides.

  1997cited by this paper
• MOLMOL: a program for display and analysis of macromolecular structures.

  1996cited by this paper
• Efforts toward deriving the CD spectrum of a 310 helix in aqueous medium

  1996cited by this paper
• PROMOTIF—A program to identify and analyze structural motifs in proteins

  1996cited by this paper
• The program XEASY for computer-supported NMR spectral analysis of biological macromolecules

  1995cited by this paper
• Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors.

  1995cited by this paper
• A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia.

  1995cited by this paper
• 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects

  1995cited by this paper
• NMR and dynamical simulated annealing studies on the solution conformation of urotensin II.

  1994cited by this paper
• Peptide hormone-membrane interactions. Intervesicular transfer of lipophilic gastrin derivatives to artificial membranes and their bioactivities.

  1993cited by this paper
• Conformational and topographical considerations in the design of biologically active peptides

  1993cited by this paper
• New evidence for a membrane-bound pathway in hormone receptor binding.

  1993cited by this paper
• How do peptides interact with lipid membranes and how does this affect their biological activity?

  1992cited by this paper
• The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy.

  1992cited by this paper
• Peptide–membrane interactions and a new principle in quantitative structure–activity relationships

  1991cited by this paper
• Current developments in G-protein-coupled receptors.

  1991cited by this paper
• Polypeptide backbone resonance assignments and secondary structure of Bacillus subtilis enzyme IIIglc determined by two-dimensional and three-dimensional heteronuclear NMR spectroscopy.

  1991cited by this paper
• Calculation of protein extinction coefficients from amino acid sequence data.

  1989cited by this paper
• NMR of proteins and nucleic acids

  1988cited by this paper
• Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces.

  1988cited by this paper
• Membrane lipid phase as catalyst for peptide-receptor interactions.

  1986cited by this paper
• Estimated conformation, orientation, and accumulation of dynorphin A-(1-13)-tridecapeptide on the surface of neutral lipid membranes.

  1986cited by this paper
• MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy

  1985cited by this paper
• Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins.

  1983cited by this paper
• Multiple quantum filters for elucidating NMR coupling networks

  1982cited by this paper
• Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.

  1980cited by this paper
• Investigation of exchange processes by two‐dimensional NMR spectroscopy

  1979cited by this paper
• Relative conformational rigidity in oxytocin and (1-penicillamine)-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism.

  1977cited by this paper
• Circular dichroism and optical rotatory dispersion of proteins and polypeptides.

  1973cited by this paper

• Characterization of human Urotensin II peptide adsorbed on silver electrode by surface-enhanced Raman scattering spectroscopy.

  2024cites this paper
• Exploring a Structural Data Mining Approach to Design Linkers for Head-to-Tail Peptide Cyclization

  2023cites this paper
• Head-to-tail peptide cyclization: new directions and application to urotensin II and Nrf2

  2022cites this paper
• Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.

  2019cites this paper
• Synthèse en phase solide de pyrrolo[3,2-e][1,4]diazépin-2-ones modulateurs du système urotensinergétique

  2017cites this paper
• Long-scale molecular dynamics simulations of cyclic peptide hormones vasopressin, urotensin and analogues

  2017cites this paper
• Conformation and Dynamics of Human Urotensin II and Urotensin Related Peptide in Aqueous Solution

  2017cites this paper
• Insight into the role of urotensin II‐related peptide tyrosine residue in UT activation

  2017cites this paper
• Structure–Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9

  2016cites this paper
• An investigation into the origin of the biased agonism associated with the urotensin II receptor activation

  2015cites this paper
• NMR spectroscopy: a useful tool for drugs development and monitoring biological reactions

  2015cites this paper
• Effect of Different Peptides

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015cites this paper
• Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.

  2014cites this paper
• Predicted Ligands for the Human Urotensin‐II G Protein‐Coupled Receptor with Some Experimental Validation

  2014cites this paper
• Urantide Conformation and Interaction with the Urotensin‐II Receptor

  2014cites this paper
• Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures

  2013cites this paper
• Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation

  2013cites this paper
• New insight into the binding mode of peptides at urotensin‐II receptor by Trp‐constrained analogues of P5U and urantide

  2013cites this paper
• Update on the urotensinergic system: new trends in receptor localization, activation, and drug design

  2012cites this paper
• β‐amino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2)

  2011cites this paper
• The effects of urotensin II and its receptor in rat renal interstitial fibrosis

  2011cites this paper
• Prediction of the Three‐Dimensional Structure for the Rat Urotensin II Receptor, and Comparison of the Antagonist Binding Sites and Binding Selectivity between Human and Rat Receptors from Atomistic Simulations

  2010cites this paper
• Membrane catalysis of peptide-receptor binding.

  2010cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Urotensin II, from fish to human

  2010cites this paper
• Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure.

  2010cites this paper
• New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

  2009cites this paper
• Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.

  2009cites this paper
• Synthèse de ligands du récepteur de l'Urotensine II et des récepteurs de la Mélatonine : composés à noyau pyrido[2,3-d]pyrimidine ou imidazo[1,2-a]pyridine

  2008cites this paper
• Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas.

  2008cites this paper
• Structure-activity relationships of urotensin II and URP.

  2008cites this paper
• Cardiovascular Activity

  2008cites this paper
• Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.

  2008cites this paper
• Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.

  2008cites this paper
• Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.

  2008cites this paper
• Therapeutic potential of blockade of the Urotensin II system in systemic hypertension

  2007cites this paper
• Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

  2007cites this paper
• Nonpeptidic ligands for peptide-activated G protein-coupled receptors.

  2007cites this paper
• Definition of New Pharmacophores for Nonpeptide Antagonists of Human Urotensin-II. Comparison with the 3D-structure of Human Urotensin-II and URP

  2007cites this paper
• Urotensin-II receptor antagonists.

  2006cites this paper
• New Urotensin-II Analogs with a Constrained Trp-7 Side Chain

  2006cites this paper
• Urotensin-II receptor ligands. From agonist to antagonist activity.

  2005cites this paper
• Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure.

  2005cites this paper
• Morphiceptin analogues containing a dipeptide mimetic structure: an investigation on the bioactive topology at the mu-receptor.

  2005cites this paper
• Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas.

  2004cites this paper